Search Results
Jeffrey Cummings, MD, ScD: Where Aducanumab Stands in Alzheimer Clinical Pipeline
Jeffrey Cummings, MD, ScD: Trends in Alzheimer Disease Clinical Pipeline
Jeffrey Cummings, MD, ScD: Repurposed Agents Within Alzheimer Disease Pipeline
Jeffrey Cummings, MD, ScD: Greatest Unmet Needs in Alzheimer Disease
Silverado Medical Director Jeffrey Cummings, MD, ScD Discusses How to Identify Early Stage Dementia
Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer Disease
Jeffrey Cummings, MD - Medpage Today
Aducanumab By Biogen - Dr Jeffrey Cummings Interview
Highlights from AD/PD: novel therapies, technologies and analytics
Drugs in the Pipeline: What’s Next and the Science Behind It
UK Alzheimer's patient positive after Biogen trials
Mayo Clinic Q&A podcast: Mayo Clinic experts discuss new Alzheimer’s treatment option
